| | □特定对象调研□分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访□业绩说明会 | | 类别 | □新闻发布会□路演活动 | | | □现场参观 | | | 其他（电话会议） | | 参与单位名称 | 中金公司 | | 时间 | 2025 年 6 月 24 日 | | 地点 | 公司 26 楼会议室 | | 上市公司接待人 | 证券事务部副总经理、证券事务代表 刘逊 | | 员姓名 | 投资者关系经理 戴晶 | | | 1、请问公司 年一季度业绩增长的驱动因素？是否具有持 2025 | | | 续性？ | | | 答：公司 年一季度实现营业收入 亿元，同比增长 2025 40.60 | | | 205.09%；归属于上市公司股东的净利润 2.45 亿元，同比增长 | | | 296.94%。营业收入与利润增加，主要系本期房地产业务销售结转增 | | | 加。随着房地产政策相关措施持续落地，市场有望逐步企稳，公司将 | | | 密切关注行业政策动态，多措并举加速房地产项目存量去化，保证现 | | | 金流安全，实现公司未来持续稳定发展。 | | 投资者关系活动 | 2、仓储 ...

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only current predictions and are subject to know ...

Core Insights - Sify Technologies Limited has appointed Dr. Ram Sewak Sharma as a new Director on its Board, bringing extensive experience in ICT and administrative reforms [1][5]. Company Overview - Sify Technologies is recognized as India's leading Digital ICT solutions provider, offering services in Data Center, Cloud, Networks, Security, and Digital services [1][7]. - The company has received multiple Golden Peacock awards for Corporate Governance, highlighting its commitment to ethical business practices [7]. Leadership and Expertise - Dr. Sharma has over four decades of experience in the Indian Administrative Service and has played a significant role in shaping India's ICT policies [2][4]. - He was the founding Director General of the Unique Identification Authority of India (UIDAI), where he was instrumental in launching Aadhaar, the world's largest biometric identity system [3][4]. - His background includes leadership roles in the telecom industry, including Chairman of the Telecom Regulatory Authority of India (TRAI) [4]. Strategic Vision - The Chairman of Sify, Mr. Raju Vegesna, expressed confidence that Dr. Sharma's experience will be a valuable asset as the company aims to strengthen its leadership position across various business segments [5]. - Dr. Sharma emphasized the importance of technology as a catalyst for implementing large-scale social welfare measures, which aligns with Sify's mission to scale its services [6]. Market Presence - Sify serves over 10,000 businesses across various sectors, leveraging its infrastructure of state-of-the-art Data Centers and the largest MPLS network in India [8][9]. - The company has a significant international presence, operating in North America, the United Kingdom, UAE, and Singapore, catering to a diverse clientele [9].

"我们希望通过本次研究成果，让全球领导者能够清晰了解哪些技术即将投入应用，这些技术将如何解 决世界范围内的紧迫问题。" 在未来三至五年里，人工智能、纳米技术、材料科学、合成生物学与生命科学领域的"技术融合"，将有 望重塑医疗健康行业的技术创新格局。与此同时，以GLP-1类药物为代表的成熟医药创新成果，正不断 探索"变革性的新应用"，回应老龄化时代里众多待满足的神经退行性疾病治疗需求。 24日，在世界经济论坛2025年新领军者年会（第十六届夏季达沃斯论坛）期间，论坛方发布《2025年十 大新兴技术报告》（下称"报告"），该报告以技术的原创性、成熟度和潜在且深远的社会效益为遴选标 准，筛选出十项有望在三至五年内取得实际成效，解决迫在眉睫的全球性挑战的新兴技术。 第一财经注意到，"健康"为这些新兴技术聚焦的重点领域之一，至少四项新兴技术直接与健康相关。 根据报告，2025年十大新兴技术分别是：纳米酶、工程化活体疗法、治疗神经退行性疾病的GLP-1类药 物、自主生化传感、协同感知、生成式水印、绿色固氮、结构电池复合材料、渗透能发电系统和先进核 能技术。其中，前四项均与医疗健康直接相关。 "我们希望通过本次研究成果，让 ...

"到2027年，黄金资源量增长5%至10%，黄金、白银产量增长5%以上"—— 工业和信息化部、国家发展改革委、自然资源部等9部门日前联合发布《黄金产业高质量发展实施方案 （2025—2027年）》。在黄金的保值和避险金融属性持续被推升的当下，实施方案亮出的这组目标数 据，引人关注。 黄金兼具商品和货币属性，对维护国家产业安全和金融安全具有重要意义。在全球地缘政治风险加剧、 世界充满不确定性背景下，黄金资源的稀缺性更加凸显。 厚植资源家底，稳固黄金产业发展根基—— 提升黄金资源量，是未来三年我国黄金产业发展的一大重点。 一季度我国黄金市场成交量、成交额呈现大幅增长，民间金条和金币投资需求快速大幅增长……黄金价 格持续攀升带动黄金投资需求激增，亟需增强资源供给保障。 我国是全球最大的黄金生产和消费国。工业和信息部数据显示，2024年，我国矿产金产量377吨，连续 18年保持全球第一；黄金消费量985吨，连续12年保持全球第一。 但也要看到，当前我国黄金资源储量仅列世界第四，大型矿山占比不足，已探明大型金矿多为中低品 位，进口金占黄金供应总量的40%左右，呈现出"产消大国、储备中等"的行业特征。 "面对'大而不强' ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

每经记者｜肖纯 每经编辑｜刘艳美 各地高考成绩陆续公布，即将进入志愿填报时间。 就在近日，两所新型研究型大学——宁波东方理工大学、大湾区大学同时获教育部批复，将于今年开始招收首批本科生。 近年来，多所新型研究型大学相继成立或筹划建设。除上述两所大学外，上海科技大学、西湖大学、南方科技大学、深圳理工大学等均已开始招生，福耀科 技大学同样于今年获批成立，钱塘大学也在加快推进。 这些年轻大学的办学定位，几乎都聚焦高起点、小而精、研究型、国际化等关键词，不仅硬件一流，而且纷纷请来大师、院士坐镇。而在这些大学的愿景 中，斯坦福、麻省理工学院、加州理工学院等顶尖名校，常被视为"对标"对象。 对广大考生和家长来说，报志愿是一道重要性不亚于高考本身的"大题"。一张志愿，实际包括城市、大学、专业三个选择。而这三个选择，正好可以作为观 察这批新型研究型大学的三个维度。 以今年即将开始招生的三所新学校为例。以城市的维度来看，三所大学全部位于经济发达的东南沿海地区，宁波、东莞、福州都是GDP超万亿、产业基础 好，且都缺乏优质教育资源的城市。 图片来源："东方理工"官方微信号 宁波东方理工大学由韦尔股份董事长虞仁荣斥资创办。该校202 ...

Core Insights - Hoth Therapeutics' investigational candidate HT-001 achieved a 100% response rate in at least one primary efficacy endpoint in its ongoing Phase 2a clinical study for EGFR inhibitor-induced skin toxicities [2][7] - The company will host a Key Opinion Leader event to discuss the interim results and potential impact of HT-001 on supportive care standards for oncology patients [1] Clinical Trial Highlights - The Phase 2a trial (CLEER-001) demonstrated that 100% of enrolled patients achieved at least one primary endpoint of clinical dermatologic improvement [7][8] - Over 65% of patients reported reductions in pain and pruritus, with 0% requiring dose reduction or discontinuation of their EGFR inhibitor therapy [7][8] - HT-001 is a once-daily topical gel that targets neuroinflammatory pathways without causing immunosuppression or systemic toxicity [4] Mechanism of Action - HT-001 is formulated with an FDA-approved neurokinin-1 receptor antagonist (NK1RA) that mitigates inflammatory pathways triggered by EGFR inhibition, particularly those driven by Substance P [4][5] - Preclinical data showed significant reductions in dermatitis and alopecia severity, as well as inflammatory markers in rat models co-treated with erlotinib [5][9] Regulatory and Development Pathway - HT-001 is being advanced under the 505(b)(2) regulatory pathway, which allows the use of existing safety data to expedite development [10] - The company is currently planning a Phase 2b/3 trial following the ongoing Phase 2a trial [13]

Group 1 - Mastercard is well-positioned to handle potential disruptions from stablecoins, with limited immediate threats to its core business despite major retailers considering their own stablecoins [1][8] - Stablecoins offer benefits like faster settlement and lower transaction costs, but lack consumer advantages such as credit access, fraud protection, and rewards, where Mastercard excels [2][8] - Mastercard is actively innovating by introducing initiatives like the Multi-Token Network and piloting USDC settlements to integrate blockchain technology into its payment systems [3][8] Group 2 - Historical technological shifts, such as mobile wallets, have complemented traditional card networks, suggesting a similar outcome may occur with stablecoins [4] - There are potential revenue risks if merchant-led stablecoin platforms gain traction faster than expected, particularly in high-fee or cross-border segments [4][5] - Overall, Mastercard's proactive innovation strategy and established consumer advantages indicate a likelihood of adapting and thriving alongside emerging technologies [5] Group 3 - Mastercard shares have increased by 3% year to date, outperforming the broader industry's decline of 0.1% [7] - The company trades at a forward price-to-earnings ratio of 31.42X, which is higher than the industry average, and carries a Value Score of D [10] - The Zacks Consensus Estimate predicts a 9.5% rise in Mastercard's fiscal 2025 earnings year over year, followed by a 16.7% growth in the subsequent year [11]

Core Business Performance - Abbott is experiencing increased global demand for routine diagnostic tests, particularly in its Diagnostics business, which accounted for 20% of total revenues in Q1 2025 [3][4] - The Diabetes Care segment is benefiting from strong sales of the FreeStyle Libre continuous glucose monitoring system, with Q1 sales exceeding $1.7 billion and growing 21.6% [5][8] - Established Pharmaceuticals (EPD) sales rose 8% organically in Q1 2025, with significant growth in emerging markets and a focus on biosimilars [10][8] Market Position and Financials - Abbott's market capitalization stands at $231.38 billion, with an earnings yield of 3.9%, significantly higher than the industry's 0.5% [2] - The company has outperformed earnings estimates in three of the last four quarters, achieving an average earnings surprise of 1.6% [2] - The Zacks Consensus Estimate for Abbott's 2025 revenues is projected at $44.68 billion, indicating a 6.5% increase from the previous year [13] Strategic Initiatives - Abbott is investing $0.5 billion in new manufacturing and R&D facilities in Illinois and Texas to enhance its U.S. transfusion diagnostics business [4] - The launch of the Alinity m system will allow Abbott to enter the molecular nucleic acid testing market, which is valued at $1 billion [4] - Abbott has secured rights to 15 biosimilar products, positioning itself for growth in the branded generic pharmaceutical market [10][9] Challenges and Risks - Macroeconomic pressures, including geopolitical tensions and rising raw material costs, are expected to impact Abbott's margins and sales [11][12] - Foreign exchange fluctuations have negatively affected Abbott's international sales, with a 2.8% unfavorable year-over-year impact reported in Q1 2025 [12]